Why Is Neuro-Oncology-Focused MediciNova Stock Trading Higher Today?

MediciNova Inc's MNOV collaborators presented new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the Annual Meeting of the Society for Neuro-Oncology

The primary endpoints of this Phase 2 clinical trial were the safety and tolerability of MN-166 (ibudilast) and temozolomide (TMZ) combination treatment and efficacy of the combination treatment defined as progression-free survival rate at six months using the RANO criteria. 

MN-166 (ibudilast) and TMZ combination treatment was safe and well-tolerated, and no unexpected adverse effects were reported.

The highlights of the presentation are as follows:

  • All of the subjects received TMZ and MN-166 (ibudilast) treatment. Progression-free survival at six months was 44% for new GBM and 31% for recurrent GBM.
  • Immunohistochemistry evaluation was performed for the patients whose pre-treatment tumor tissue samples were available from resected tumors at the initial surgery or biopsy to evaluate MIF (macrophage migration inhibitory factor), pERK, Ki67, CD3, CD11b, and CD74.
  • CD3 expression was a good predictor for tumor progression at five months in recurrent glioblastoma subjects treated with MN-166 (ibudilast) and TMZ, as subjects with progression had higher CD3 tumor infiltration than subjects with no progression (p<0.05)

The presentation also included data from preclinical studies that evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.

  • Median survival was 17 days for the vehicle and 28 days for the anti-PD1 inhibitor treatment alone. The addition of MN-166 (ibudilast) to the anti-PD1 inhibitor treatment significantly extended survival to a median of 66 days (p<0.001) for the combination therapy.
  • Median survival was 18 days for the vehicle and 26 days for the anti-PD-L1 inhibitor treatment alone. The addition of MN-166 (ibudilast) to the anti-PD-L1 inhibitor treatment significantly extended survival to a median of 34 days (p<0.05) for the combination therapy.

Price Action: MNOV shares are up 14.3% at $2.04 on the last check Monday.

Photo Via Company

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechEquitiesNewsPenny StocksHealth CareMarketsMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!